Burning Rock Biotech Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third Quarter 2026 Financial Results | 10 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly107.9M
Gross Margin Quarterly7,230.0%
Operating Expenses Quarterly96.9M
Number of Partner Hospitals Quarterly94
Watch Items
- Transition from central laboratory testing to in-hospital testing modelTrigger: In-hospital revenue share of total revenue dropping below 45%Action: Re-evaluate sales strategy and hospital partnership terms to accelerate in-hospital kit adoption.
- Cash burn rate and liquidity runwayTrigger: Cash and cash equivalents dropping below RMB 300 millionAction: Initiate strategic financing discussions or implement further cost-reduction measures in R&D and G&A.
Research as of 20 Jun 2026